Combination of PD‐1 inhibitor and targeted therapy in advanced BRAF V600E‐mutant melanoma with symptomatic brain metastases: a report of five cases

Symptomatic brain metastases in melanoma

“…Combining BRAF‐MEK inhibitors with PD‐1/PD‐L1 inhibitors has been trialled and considered as a bridging option in symptomatic MBM, but has limited data to support it as routine practice. A case series of five patients, all with symptomatic brain metastases, demonstrated that the combination of BRAF‐MEK inhibitors and PD‐1 inhibitor (and radiation) could produce durable responses, with two patients experiencing a complete response, and more than 3 years without progression 78 . Initial results from the TRIDeNT phase II study, including ten MBM patients (some symptomatic), treated with nivolumab, dabrafenib and trametinib, reported an intracranial response of 57% 79 …”